Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This therapeutic regimen is designed for the treatment of advanced nasopharyngeal carcinoma (NPC), specifically targeting patients with N2-3 stage disease. The protocol consists of concurrent chemoradiotherapy (CCRT) followed by adjuvant chemotherapy. During the CCRT phase, patients receive concurrent cisplatin (a platinum-based DNA cross-linking agent) alongside intensity-modulated radiotherapy (IMRT). This is followed by an adjuvant chemotherapy phase known as the PF regimen, which combines cisplatin with 5-fluorouracil (5-FU). 5-fluorouracil is a pyrimidine analog antimetabolite that inhibits thymidylate synthase, thereby interfering with DNA synthesis. This specific treatment sequence was evaluated in a Phase 3 clinical trial conducted by Sun Yat-sen University to compare its efficacy and safety against a gemcitabine plus cisplatin (GP) adjuvant regimen.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cisplatin + fluorouracil + radiotherapy (Sun Yat-sen University).